Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
COMPASS Pathways ( (CMPS) ) just unveiled an announcement.
On January 5, 2026, COMPASS Pathways and certain subsidiaries entered into a third amendment to their loan and security agreement with Hercules Capital, expanding the facility to provide up to $150 million in term loans across five milestone-based tranches, including an immediate $50 million draw of which about $31.1 million will repay existing indebtedness. The amended agreement locks in an interest-only period until at least early 2029, sets a maturity date of January 5, 2031, and adds a mix of facility, end-of-term and prepayment charges, while maintaining collateralization over substantially all personal property and customary covenants and default provisions; the structure ties further borrowing capacity and certain financial covenants to the company’s achievement of clinical, FDA approval and commercial milestones for its lead product candidate, providing extended runway but also embedding performance and cash-balance requirements that will be closely watched by lenders and investors.
The most recent analyst rating on (CMPS) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on COMPASS Pathways stock, see the CMPS Stock Forecast page.
Spark’s Take on CMPS Stock
According to Spark, TipRanks’ AI Analyst, CMPS is a Neutral.
The score is held back primarily by weak financial performance (no revenue, worsening losses and cash burn, and reduced equity with higher leverage). Offsetting factors include constructive technical momentum and a strong earnings-call update driven by positive Phase III results, accelerated regulatory/launch timelines, and a stated cash runway into 2027.
To see Spark’s full report on CMPS stock, click here.
More about COMPASS Pathways
COMPASS Pathways plc operates in the biopharmaceutical sector, focusing on the development of psychedelic-based therapies, with a lead product candidate aimed at addressing significant unmet needs in mental health. The company’s financing arrangements are closely tied to the clinical, regulatory and commercial progress of this lead candidate, reflecting a development-stage business model where access to non-dilutive capital is linked to milestone achievements.
Average Trading Volume: 1,634,025
Technical Sentiment Signal: Buy
Current Market Cap: $629.8M
For an in-depth examination of CMPS stock, go to TipRanks’ Overview page.